Abstract:
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Abstract:
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Abstract:
The present invention relates to an Aβ(X - 38.. 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aβ(X - 38.. 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aβ(X - 38.. 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.
Abstract:
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Abstract:
The present invention relates to amyloid-beta (As) binding proteins. Antibodies of the invention have high affinity to As(20-42) globulomer or any A form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
Abstract:
The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
Abstract:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
Abstract:
The present invention relates to amyloid-beta (Αβ) binding proteins. Antibodies of the inven- tion have high affinity to Αβ(20-42) globulomer or any Αβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
Abstract:
The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.
Abstract:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.